Sarepta Therapeutics' licensing partner Arrowhead Pharmaceuticals said on Wednesday it expects to receive near-term milestone ...

We recently published 10 Big Names Get Slammed. Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) is one of the biggest losers on ...

The Sarepta agreement reduces financial risk and lends credence to Arrowhead's platform. Within this context, Arrowhead appears conservatively valued, at a market capitalization near $2.75 billion.

On the other hand, H.C. Wainwright raised Arrowhead's stock price target from $60.00 to $80.00, citing the company's recent global license and collaboration agreement with Sarepta Therapeutics.

The financial aspect of the partnership with Sarepta is significant for Arrowhead, with the upfront and equity investments estimated to bolster the company's pro forma cash to $1.5 billion.

Arrowhead Pharmaceuticals (ARWR) has secured a new partnership with Sarepta Therapeutics (SRPT). Under the terms of the deal, Sarepta will pay Arrowhead $500 million upfront and make a $325 ...

Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced an exclusive global licensing and collaboration agreement with Arrowhead ...

In addition, Sarepta and Arrowhead have entered into a discovery collaboration for up to six additional muscle, cardiac, and/or CNS targets, using Arrowhead’s novel delivery technologies. As part of ...

Sarepta pauses U.S. Elevidys shipments to complete FDA-requested safety label updates, aiming to resume distribution in the fourth quarter.

TD Cowen analyst Brendan Smith has maintained their bullish stance on ARWR stock, giving a Buy rating on November 20. Don't Miss our Black Friday Offers: Brendan Smith has given his Buy rating due ...

Arrowhead Pharmaceuticals said on Wednesday it expects to receive near-term milestone payments from Sarepta Therapeutics as ...

Arrowhead has received a $500 million upfront payment in addition to $325 million through Sarepta’s purchase of Arrowhead common stock at $27.25 per share. Over the next five years, Arrowhead is set ...